RT Journal Article
T1 Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
A1 Alonso, S
A1 Riveiro-Barciela, M
A1 Fernandez, I
A1 Rincón, D
A1 Real, Y
A1 Llerena, S
A1 Gea, F
A1 Olveira, A
A1 Fernandez-Carrillo, C
A1 Polo, B
A1 Carrión, J A
A1 Gómez, A
A1 Devesa, M J
A1 Baliellas, C
A1 Castro, Á
A1 Ampuero, J
A1 Granados, R
A1 Pascasio, J M
A1 Rubín, A
A1 Salmeron, J
A1 Badia, E
A1 Planas, J M M
A1 Lens, S
A1 Turnes, J
A1 Montero, J L
A1 Buti, M
A1 Esteban, R
A1 Fernández-Rodríguez, C M
K1 SVR12
K1 cirrhosis
K1 daclatasvir
K1 genotype 3
K1 hepatitis C
K1 ledipasvir
K1 observational study
K1 real-world cohort
K1 sofosbuvir
AB Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical practice in this population. This was a multicenter observational study including cirrhotic patients infected by HCV GT3, treated with sofosbuvir plus an NS5A inhibitor (May 2014-October 2015). In total, 208 patients were included: 98 (47%) treatment-experienced, 42 (20%) decompensated and 55 (27%) MELD score >10. In 131 (63%), treatment was SOF+DCV and in 77 (37%), SOF/LDV. Overall, 86% received RBV. RBV addition and extension to 24 weeks was higher in the SOF/LDV group (95% vs 80%, P=.002 and 83% vs 72%, P=.044, respectively). A higher percentage of decompensated patients were treated with DCV than LDV (25% vs 12%, P=.013). Overall, SVR12 was 93.8% (195/208): 94% with SOF+DCV and 93.5% with SOF/LDV. SVR12 was achieved in 90.5% of decompensated patients. Eleven treatment failures: 10 relapses and one breakthrough. RBV addition did not improve SVR (RR: 1.08; P=.919). The single factor associated with failure to achieve SVR was platelet count 10. In 131 (63%), treatment was SOF+DCV and in 77 (37%), SOF/LDV. Overall, 86% received RBV. RBV addition and extension to 24 weeks was higher in the SOF/LDV group (95% vs 80%, P=.002 and 83% vs 72%, P=.044, respectively). A higher percentage of decompensated patients were treated with DCV than LDV (25% vs 12%, P=.013). Overall, SVR12 was 93.8% (195/208): 94% with SOF+DCV and 93.5% with SOF/LDV. SVR12 was achieved in 90.5% of decompensated patients. Eleven treatment failures: 10 relapses and one breakthrough. RBV addition did not improve SVR (RR: 1.08; P=.919). The single factor associated with failure to achieve SVR was platelet count
YR 2016
FD 2016-12-09
LK http://hdl.handle.net/10668/10667
UL http://hdl.handle.net/10668/10667
LA en
DS RISalud
RD Apr 17, 2025